![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » Velcade for Multiple Myeloma Retreatment Clinical Trial Initiated
Velcade for Multiple Myeloma Retreatment Clinical Trial Initiated
Millennium Pharmaceuticals has initiated EVEREST (Evaluation of Velcade Employed as Retreatment for Efficacy, Safety and Tolerability).
This is a multicenter, Phase IV clinical trial of Velcade in multiple myeloma patients who have previously responded to Velcade and relapsed following a treatment-free remission. Efficacy of retreatment with Velcade will be assessed in terms of best-confirmed M-protein response.
The open-label, clinical trial will be conducted at approximately 80 sites in North America and will enroll up to approximately 120 patients. Eligible patients need to have tolerated 1- or 1.3-mg/m2 doses of Velcade alone or in combination with dexamethasone, have had a reduction of M-protein of 50 percent or more that has lasted at least six months with a treatment-free interval of at least four months. In the EVEREST trial, the maximum number of cycles will be dependent on patient response and investigator discretion.
KEYWORDS Drug Pipeline Alert
Upcoming Events
-
11Jul
-
18Jul
-
21Oct